Hostname: page-component-77f85d65b8-7lfxl Total loading time: 0 Render date: 2026-04-22T02:28:41.121Z Has data issue: false hasContentIssue false
  • English
  • Français

A European Study of Views on the Use of Monoamine Oxidase Inhibitors

Published online by Cambridge University Press:  06 August 2018

E.S. Paykel  and
J.L. White
E.S. Paykel
Affiliation:
University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
J.L. White
Affiliation:
Medical Action Communications, Egham, Surrey, UK
Get access Rights & Permissions [Opens in a new window]

Abstract

A total of 1269 psychiatrists, from 15 European countries, completed a questionnaire assessing treatment choice in depressive and anxiety disorders, with particular focus on diagnostic and other factors determining use of monoamine oxidase inhibitors (MAOIs). Tricyclic and similar antidepressants were used most commonly — MAOIs were used as first-choice therapy for depressive or anxiety disorders only by a minority but were commonly a second-choice treatment for atypical depressives. Use was inhibited by interactions and side-effects rather than by perceived ineffectiveness. Cross-national differences in treatment were considerable but diagnostic differences in case history vignettes were much smaller.

Information

Type
Research Article
Information
The British Journal of Psychiatry , Volume 155 , Issue S6: Depression and Reversible Monoamine Oxidase Inhibitors-New Perspectives , October 1989 , pp. 9 - 17
Copyright
Copyright © 1989 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Blackwell, B. (1963) Tranylcypromine. Lancet, i, 414.CrossRefGoogle Scholar
Buiges, J. & Vallejo, J. (1987) Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. Journal of Clinical Psychiatry, 48, 55–59.Google Scholar
Davidson, J.R.T., Giller, E.L., Zisook, S., et al (1988) An efficacy study of isocarboxazid and placebo in depression and its relationship to depressive nosology. Archives of General Psychiatry, 45, 120–127.Google Scholar
Greenblatt, M., Grosser, G.M. & Wechsler, H. (1964) Differential response of hospitalized depressed patients to somatic therapy. American Journal of Psychiatry, 120, 935–943.Google Scholar
Hall, W., Weekes, P., Harvey, R., et al (1982) A survey of practising psychiatrists views on the treatment of agoraphobia. Australia and New Zealand Journal of Psychiatry, 16, 225–233.Google Scholar
Liebowitz, M.R., Quitkin, F.M., Stewart, J.W., et al (1984) Phenelzine v imipramine in atypical depression: a preliminary report. Archives of General Psychiatry, 41, 669–677.Google Scholar
Liebowitz, M.R., Quitkin, F.M., Stewart, J.W., et al (1988) Antidepressant specificity in atypical depression. Archives of General Psychiatry, 45, 129–137.CrossRefGoogle ScholarPubMed
McGilchrist, J.M. (1975) Interactions with monoamine oxidase inhibitors. British Medical Journal, 271, 591–592.CrossRefGoogle Scholar
Medical Research Council (1965) Clinical trial of the treatment of depressive illness. British Medical Journal, i, 881–886.Google Scholar
Pare, C.M.B. (1985) The present status of monoamine oxidase inhibitors. British Journal of Psychiatry, 146, 576–584.Google Scholar
Paykel, E.S., Rowan, P.R., Parker, R.R., et al (1982) Response to phenelzine and amitriptyline in subtypes of outpatient depression. Archives of General Psychiatry, 39, 1041–1049.Google Scholar
Paykel, E.S., Parker, R.R., Rowan, P.R., et al (1983) Nosology of atypical depression. Psychological Medicine, 13, 131–139.CrossRefGoogle ScholarPubMed
Raskin, A., Schulterbrandt, J.G., Reatig, N., et al (1974) Depression subtypes and response to phenelzine, diazepam and a placebo. Archives of General Psychiatry, 30, 66–75.CrossRefGoogle ScholarPubMed
Ravaris, C.L., Robinson, D.S., Ives, J.O., et al (1980) Phenelzine and amitriptyline in the treatment of depression. Archives of General Psychiatry, 37, 1076–1080.CrossRefGoogle ScholarPubMed
Tyrer, P.J. (1976) Towards rational prescribing with MAOIs. British Journal of Psychiatry, 128, 354–360.CrossRefGoogle Scholar
Tyrer, P.J., Candy, J. & Kelly, D. (1973) A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologica (Berlin), 32, 237–254.CrossRefGoogle ScholarPubMed
West, E.D. & Dally, P.J. (1959) Effects of iproniazid in depressive syndromes. British Medical Journal, i, 1491–1499.CrossRefGoogle Scholar

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.